ACC Cardiovascular Summit Virtual Details: Keynote by Anthony S. Fauci, MD.

January 28, 2021

ACC Cardiology’s Cardiovascular Summit Virtual will feature two days of live content on Feb. 12-13, 2021, including the Leadership Forum keynote speech delivered by National Institute of Allergy and Infectious Disease Director Anthony S. Fauci, MD.

Course director Bo Walpole, MD, FACC, and course co-directors Geoffrey Rose, MD, FACC, and Cathleen Biga, MSN, FACC, have invited leaders from across private, integrated and academic practices to create a course intended for all cardiovascular practices and the entire cardiovascular care team. The conference aims to provide strategies and tools that will advance the concepts of the Quadruple Aim—improved patient experience, care team well-being, smarter spending and better health outcomes—within the work environment. The course will also address the unprecedented change experienced within the health care system since the start of the COVID-19 pandemic through relevant live sessions and on-demand content.

Live Sessions Include:

  • Mobilizing and Operationalizing Rapid Change – Christopher Fussell, President, McChrystal Group – Friday, Feb. 12, 2021 at 8:30 a.m. ET
  • COVID-19: Public Health and Scientific Challenges – Anthony S. Fauci, MD, Director, NIAID – Friday, Feb. 12, 2021 at 12:10 p.m. ET
  • CV Care in Unusual Places: Delivering Value Beyond Bricks and Mortar – Saturday, Feb. 13, 2021 at 10:25 a.m. ET
  • Telehealth – Cool Accessory or Essential Component of Health Care Delivery – Saturday, Feb. 13, 2021 at 11:00 a.m. ET

The course will also feature on-demand content available beginning on Monday, Feb. 1, 2021, which will be available for three months.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”